Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Xolair on Airway Hyperresponsiveness
NCT00208234Phase 4Unknown
- Sponsor
- Creighton University
- Start
- Jan 2004
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma comparing Placebo with Omalizumab (2 arms). Primary endpoints: Provocative Concentration of Methacholine causing a 20% fall in FEV1 and Provocative Concentration of Hypertonic Saline causing a 15% fall in FEV1. Status: unknown.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00208234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00208234.